# Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement

Study · id `cardio:ct-nct07090343` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07090343](<https://clinicaltrials.gov/study/NCT07090343>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07090343

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 826 participants.

## Technical summary

Registry record NCT07090343. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-01 (anticipated); primary completion 2030-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 826 participants (planned count; ClinicalTrials.gov record NCT07090343, source copy `cardio:ctgov-nct07090343-2025-07-29`, retrieved 2026-10-26)
- Planned start: 2026-04-01 (anticipated) (ClinicalTrials.gov record NCT07090343, source copy `cardio:ctgov-nct07090343-2025-07-29`, retrieved 2026-10-26)
- Primary completion: 2030-09-01 (anticipated) (ClinicalTrials.gov record NCT07090343, source copy `cardio:ctgov-nct07090343-2025-07-29`, retrieved 2026-10-26)
- Completion: 2031-04-01 (anticipated) (ClinicalTrials.gov record NCT07090343, source copy `cardio:ctgov-nct07090343-2025-07-29`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07090343-2025-07-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
- Acronym: REVERSE-TAVR
- Condition: Aortic Stenosis
- Condition: Heart Failure
- Intervention (Drug): Wegovy ®
- Intervention (Drug): Placebo
- Lead sponsor: Leiden University Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Semaglutide injection for weight management (Wegovy) (`cardio:wegovy`)
- Registry lists this organization as the lead sponsor: Leiden University Medical Center (`cardio:org-leiden-university-medical-center`)

## Provenance

Content hash: 723a7b9859750533b7e900dd1e814a8f25eb9c86e75e4eb7e3e31b5c60461297
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
